WallStSmart

Pfizer Inc (PFE)vsValmont Industries Inc (VMI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 1425% more annual revenue ($62.58B vs $4.10B). PFE leads profitability with a 12.4% profit margin vs 8.5%. VMI appears more attractively valued with a PEG of 1.55. VMI earns a higher WallStSmart Score of 63/100 (C+).

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9

VMI

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 7.0Value: 10.0Quality: 6.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PFESignificantly Overvalued (-194.9%)

Margin of Safety

-194.9%

Fair Value

$9.25

Current Price

$27.28

$18.03 premium

UndervaluedFair: $9.25Overvalued
VMIUndervalued (+39.1%)

Margin of Safety

+39.1%

Fair Value

$785.30

Current Price

$406.39

$378.91 discount

UndervaluedFair: $785.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.36B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

VMI3 strengths · Avg: 9.7/10
EPS GrowthGrowth
135.3%10/10

Earnings expanding 135.3% YoY

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Return on EquityProfitability
21.9%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

VMI3 concerns · Avg: 3.7/10
PEG RatioValuation
1.554/10

Expensive relative to growth rate

Revenue GrowthGrowth
0.1%4/10

0.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bull Case : VMI

The strongest argument for VMI centers on EPS Growth, Debt/Equity, Return on Equity.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Bear Case : VMI

The primary concerns for VMI are PEG Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

PFE profiles as a declining stock while VMI is a value play — different risk/reward profiles.

VMI carries more volatility with a beta of 1.21 — expect wider price swings.

VMI is growing revenue faster at 0.1% — sustainability is the question.

PFE generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

VMI scores higher overall (63/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Valmont Industries Inc

INDUSTRIALS · CONGLOMERATES · USA

Valmont Industries, Inc. produces and sells metal products manufactured in the United States, Australia, Denmark, and internationally. The company is headquartered in Omaha, Nebraska.

Visit Website →

Want to dig deeper into these stocks?